Outlook
- To print this page, please use the File menu or press simultaneously ctrl + p keys.
- Send this page
Our guidance is established following information, assumptions and intentions that may be, completely our partially, based on assumptions and decisions of the sanofi-aventis management that could evolve or change in the future.
2010 Guidance
Despite expected generic competition, and given the performance of growth platforms, sanofi-aventis expects growth* in Business EPS at constant exchange rates to be between 2% and 5% in 2010, barring major unforeseen adverse events. This guidance does not take into account potential generic competition for Lovenox®.
* This growth estimate is based on 2009 Business EPS of €6.61; see Appendix 9 of the 2009 Annual Results Press Release for definition:
Update of 2009 guidance announced on October 30, 2009
Based on the good performance achieved over the first nine months of the year, and the expected contribution from approximately $500 million of H1N1 vaccine sales in the fourth quarter, sanofi-aventis has updated its guidance for 2009 full-year growth in adjusted EPS excluding selected items** of around 11%, calculated at constant exchange rates and barring major adverse events.
Increase in 2009 guidance announced on July 29, 2009
Following a good first-half performance, sanofi-aventis has raised its 2009 full-year guidance. We now expect growth in adjusted EPS excluding selected items** for the year to be around 10%, calculated at constant exchange rates, barring major adverse events.
2009 guidance announced on February 11, 2009 and confirmed on April 29, 2009
In 2009, sanofi-aventis expects growth in adjusted EPS excluding selected items** of at least 7% at constant exchange rates, barring major adverse events such as the launch of a generic of Lovenox® in the United States.
** See definition of adjusted earnings per share (adjusted EPS) in our Glossary.
Cautionary statement regarding forward-looking statements
This page contains projections and other forward-looking statements that are not historical facts. Although the management of sanofi-aventis believes that these projections and forward-looking statements, and their underlying assumptions, are reasonable as of the date of publication, investors are cautioned that such projections, assumptions, intentions and forward-looking statements are subject to various risks and uncertainties (many of which are difficult to predict and generally beyond the control of sanofi-aventis) that could cause actual results and developments to differ materially from those expressed or implied. These risks and uncertainties include those discussed elsewhere in the filings of sanofi-aventis with the U.S. Securities and Exchange Commission (SEC) and the French Autorité des marchés financiers (AMF), notably under the caption “Risk Factors” in the company’s annual report on Form 20-F. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update any statement that is not a historical fact.
Further information on risk factors:
